What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Myocardial infarction
His primary areas of study are Surgery, Stent, Myocardial infarction, Internal medicine and Cardiology.
His Surgery research is multidisciplinary, incorporating elements of Clinical trial, Angioplasty and Revascularization.
His Stent study integrates concerns from other disciplines, such as Thrombosis, Ticlopidine, Randomized controlled trial and Hazard ratio.
The study incorporates disciplines such as Restenosis, Coronary stent, Stroke, Everolimus and Radiology in addition to Myocardial infarction.
His Treatment outcome and Myocardial infarction diagnosis study in the realm of Internal medicine connects with subjects such as Adjudication and Addendum.
His Cardiology course of study focuses on Platelet aggregation inhibitor and Thienopyridine.
His most cited work include:
- Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions (4102 citations)
- Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. (2883 citations)
- Protected Carotid-Artery Stenting versus Endarterectomy in High-Risk Patients (2326 citations)
What are the main themes of his work throughout his whole career to date?
Donald E. Cutlip focuses on Internal medicine, Cardiology, Myocardial infarction, Surgery and Stent.
His biological study spans a wide range of topics, including Radiology and Renal function.
The concepts of his Myocardial infarction study are interwoven with issues in Stroke and Hazard ratio.
In his study, which falls under the umbrella issue of Surgery, Intensive care medicine is strongly linked to Clinical trial.
His Stent research is multidisciplinary, relying on both Clinical endpoint, Mace and Sirolimus.
Donald E. Cutlip has researched Percutaneous coronary intervention in several fields, including Aspirin and Conventional PCI.
He most often published in these fields:
- Internal medicine (73.61%)
- Cardiology (65.96%)
- Myocardial infarction (53.03%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (73.61%)
- Cardiology (65.96%)
- Percutaneous coronary intervention (33.51%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Cardiology, Percutaneous coronary intervention, Myocardial infarction and Surgery.
His work deals with themes such as Platelet aggregation inhibitor, Renal artery and Albuminuria, Renal function, which intersect with Cardiology.
Donald E. Cutlip has included themes like Coronary artery disease, Conventional PCI, Acute coronary syndrome and Intensive care medicine in his Percutaneous coronary intervention study.
As a part of the same scientific family, Donald E. Cutlip mostly works in the field of Myocardial infarction, focusing on Coronary stent and, on occasion, Randomization.
He is involved in the study of Surgery that focuses on Stent in particular.
His work carried out in the field of Stent brings together such families of science as Clinical endpoint, Randomized controlled trial, Durable polymer and Sirolimus.
Between 2015 and 2021, his most popular works were:
- Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. (482 citations)
- Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. (482 citations)
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention : A Consensus Document From the Academic Research Consortium for High Bleeding Risk (189 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Myocardial infarction
His primary areas of investigation include Percutaneous coronary intervention, Surgery, Internal medicine, Cardiology and Myocardial infarction.
In the field of Percutaneous coronary intervention, his study on Everolimus eluting stent and Durable polymer overlaps with subjects such as In patient and Bioresorbable polymers.
Many of his research projects under Surgery are closely connected to Statement with Statement, tying the diverse disciplines of science together.
His work focuses on many connections between Stent and other disciplines, such as Randomized controlled trial, that overlap with his field of interest in Everolimus and Target lesion.
His study in Cardiology is interdisciplinary in nature, drawing from both Renal replacement therapy, Creatinine, Renal Artery Obstruction and Albuminuria, Kidney.
His Stroke research incorporates themes from Odds ratio and Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
